Related references
Note: Only part of the references are listed.Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
Mehdi Hamadani et al.
BLOOD (2021)
A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806
Hui K. Gan et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Unlocking the potential of antibody-drug conjugates for cancer therapy
Joshua Z. Drago et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer
Preeti Narayan et al.
CLINICAL CANCER RESEARCH (2021)
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
A. Bardia et al.
ANNALS OF ONCOLOGY (2021)
Loncastuximab Tesirine: First Approval
Arnold Lee
DRUGS (2021)
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
Emanuela Ferraro et al.
BREAST CANCER RESEARCH (2021)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR
James M. Cleary et al.
INVESTIGATIONAL NEW DRUGS (2020)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan
David M. Goldenberg et al.
MABS (2019)
A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation
Nicholas C. Yoder et al.
MOLECULAR PHARMACEUTICS (2019)
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Kevin O. Saunders
FRONTIERS IN IMMUNOLOGY (2019)
Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer
Hyung Kwon Byeon et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
Emerging functions of the EGFR in cancer
Sara Sigismund et al.
MOLECULAR ONCOLOGY (2018)
Efficacy and Safety Results of Depatuxizumab Mafodotin (ABT-414) in Patients With Advanced Solid Tumors Likely to Overexpress Epidermal Growth Factor Receptor
Glenwood D. Goss et al.
CANCER (2018)
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
Andrew C. Phillips et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Zhenyi An et al.
ONCOGENE (2018)
Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine
John A. Hartley et al.
SCIENTIFIC REPORTS (2018)
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Alexander H. Staudacher et al.
BRITISH JOURNAL OF CANCER (2017)
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Joerg Felsberg et al.
CLINICAL CANCER RESEARCH (2017)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Linkers Having a Crucial Role in Antibody-Drug Conjugates
Jun Lu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload
Arnaud C. Tiberghien et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Current ADC Linker Chemistry
Nareshkumar Jain et al.
PHARMACEUTICAL RESEARCH (2015)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer
John M. Lambert et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases
Mark A. Lemmon et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Epidermal Growth Factor Receptor Variant III Contributes to Cancer Stem Cell Phenotypes in Invasive Breast Carcinoma
Catherine A. Del Vecchio et al.
CANCER RESEARCH (2012)
Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy
Hui K. Gan et al.
CANCER RESEARCH (2012)
The ERBB network: at last, cancer therapy meets systems biology
Yosef Yarden et al.
NATURE REVIEWS CANCER (2012)
Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer
Aleksandra Franovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
Andrew M. Scott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers - Implications for combination therapy with monoclonal antibody 806
Hui K. Gan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
AA Jungbluth et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)